Novo Nordisk to test best-selling substance in stroke indication
![Photo: Novo Nordisk / PR/Henning Larsen Architects](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14639080/wzx9t1/ALTERNATES/schema-16_9/doc7ntw7me6dno4xnw1hwm.jpg)
Novo Nordisk is planning to test its best-selling substance semaglutide, which is already approved within the treatment of diabetes and obesity, in non-diabetic patients who have suffered severe ischemic strokes, trial database Clinical Trials reveals.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Zealand Pharma CEO has high hopes for obesity candidate
For subscribers